Most Recent Articles by Laura Stiles
Lofexidine may expand the treatment options available for managing withdrawal when buprenorphine and methadone are unavailable or undesirable.
Borderline personality disorder, a disorder that is often misunderstood by the general public, also raises questions for psychiatrists.
At 6 weeks of treatment, severely ill patients treated with adjunctive brexpiprazole had a greater reduction in PANSS total scores and CGI-S scores compared with those receiving placebo.
This research provides further support to compelling data linking inflammation and depression.
The researchers believe this study is the first to detect a statistically significant, unexpected inverse association between efavirenz use and depression.
More Articles by Laura Stiles
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- The Challenges of Identifying Biomarkers of Psychiatric Illness
- FDA Approves Powerful New Opioid Despite Criticisms
- Impulsivity in Bipolar Disorder, Borderline Personality Disorder, ADHD
- Oral Therapy for Suicidal Bipolar Depression Gets Breakthrough Designation
- Cannabis Use in Adolescence Associated With Poorer Mental Health Outcomes
- Updates in Borderline Personality Disorder: Your Questions Answered
- Violent Video Games Tied to Physical Aggression
- Shame Drives Suicidal Ideation Among Veterans With PTSD
- Long-term Healthy Diet Associated With Greater Hippocampal Volumes
- FDA to Ban Most Flavored Electronic Cigarettes
- Predictors of CBT Outcomes Identified in Youths With Anxiety Disorders
- Happy Childhood Memories Associated With Better Health
- FDA Launches MyStudies Mobile App in Effort to Increase Access to Real World Patient Data
- Heart Rate Variability Predicts Treatment Response in Anxious Depression